Edition:
United States

Meda AB (MEDAa.ST)

MEDAa.ST on Stockholm Stock Exchange

157.40SEK
7:02am EDT
Change (% chg)

0.10kr (+0.06%)
Prev Close
157.30kr
Open
157.00kr
Day's High
157.40kr
Day's Low
156.70kr
Volume
56,444
Avg. Vol
627,368
52-wk High
158.20kr
52-wk Low
81.75kr

MEDAa.ST

Chart for MEDAa.ST

About

Meda AB is a Sweden-based company active in the specialty pharmaceuticals sector. Its portfolio comprises products in the areas of respiratory, cardiology, pain and inflammation, dermatology, gastroenterology and CNS (central nervous system), as well as a range of over the counter (OTC) products. Its operations are organized in... (more)

Overall

Beta: 0.90
Market Cap(Mil.): kr57,488.02
Shares Outstanding(Mil.): 365.47
Dividend: 2.50
Yield (%): 1.59

Financials

  MEDAa.ST Industry Sector
P/E (TTM): 50.12 36.91 37.71
EPS (TTM): 3.14 -- --
ROI: 2.18 15.22 14.43
ROE: 5.58 16.27 15.61

BRIEF-Meda Q2 adjusted operating profit beats forecasts

* Q2 EBITDA, excluding non-recurring items, was SEK 1,576 million

Jul 21 2016

Mylan gets EU approval for Meda purchase, subject to conditions

BRUSSELS EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets.

Jul 20 2016

Mylan gets EU approval for Meda purchase, subject to conditions

BRUSSELS, July 20 EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets.

Jul 20 2016

Mylan to get EU green light for Swedish drugmaker deal -sources

U.S. generic drugmaker Mylan is expected to win conditional EU antitrust approval for its planned takeover of Swedish rival Meda AB after agreeing to shed some assets, two people familiar with the matter said on Friday.

Jul 15 2016

Exclusive: Mylan to get EU green light for Swedish drugmaker deal - sources

BRUSSELS U.S. generic drugmaker Mylan is expected to win conditional EU antitrust approval for its planned takeover of Swedish rival Meda AB after agreeing to shed some assets, two people familiar with the matter said on Friday.

Jul 15 2016

Mylan offers EC concessions to get approval for $7.2 bln Meda buy

BRUSSELS, June 30 - U.S. generic drugmaker Mylan NV has offered concessions in a bid to allay concerns by EU competition regulators over its proposed $7.2-billion acquisition of Swedish rival Meda, the European Commission said on Thursday.

Jun 30 2016

BRIEF-Mylan NV confirms that Attorney General of Netherlands has rejected request of VEB

* Says confirmed that Attorney General of Netherlands has rejected request of Dutch group VEB

Jun 20 2016

EU regulators to rule on Mylan's $7.2 billion Meda bid by July 6

BRUSSELS - European Union antitrust regulators will rule by July 6 whether to allow U.S. generic drugmaker Mylan NV to buy Swedish peer Meda or open a full-scale investigation.

Jun 02 2016

EU regulators to rule on Mylan's $7.2 bln Meda bid by July 6

BRUSSELS, June 2 - European Union antitrust regulators will rule by July 6 whether to allow U.S. generic drugmaker Mylan NV to buy Swedish peer Meda or open a full-scale investigation.

Jun 02 2016

BRIEF-Meda core profit falls to 1.26 bln SEK in Q1

* Q1 ebitda, excluding non-recurring items, was sek 1,256 million

May 03 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00
Provider : GlobalData
$300.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.